CytoSorbents Corporation · NASDAQ:CTSO

CytoSorbents — Q3 2022 Earnings Presentation

39 slides from CytoSorbents's earnings presentation, Nov 3, 2022

  1. Slide 1: The Unrecognized Faces of Critical Illness

    The Unrecognized Faces of Critical Illness CytoSorbents Corporation Third Quarter 2022 Earnings Conference Call November 3, 2022

  2. Slide 2: Conference Call Participants

    Conference Call Participants Moderator: Michelle Almonte CytoSorbents Corporation Phillip Chan, MD, PhD – Chief Executive Officer Vincent Capponi, MS – President and Chief Operating Officer Kathleen Bloch, MBA, CPA – Chief Financial Officer Efthymios “Makis” Deliargyris, MD, FACC, FESC, FSCAI – Chie

  3. Slide 3: Safe Harbor Statement

    Safe Harbor Statement Statements in this presentation regarding CytoSorbents Corporation and its operating subsidiaries CytoSorbents Medical, Inc and CytoSorbents Europe GmbH that are not historical facts are forward- looking statements and are subject to risks and uncertainties that could cause act

  4. Slide 4: Operational Update

    Operational Update Phillip Chan, MD, PhD Chief Executive Officer

  5. Slide 5: Recent Operational Highlights

    Recent Operational Highlights • More than 186,000 cumulative CytoSorb devices utilized as of 9/30/22, from >152,000 last year • Announced final key data from the U.S. CTC Registry on 100 critically ill COVID-19 patients with refractory respiratory failure from 5 sites, where Enhanced Lung Rest with

  6. Slide 6: Financial Highlights

    Financial Highlights Kathleen Bloch, MBA, CPA Chief Financial Officer

  7. Slide 7: Q3 2022 Comparative Revenue Results

    Q3 2022 Comparative Revenue Results Quarter Ended Quarter Ended Y-Y % Sept. 30, 2022 Sept. 30, 2021 Trend Product revenue $6.5M $8.9M (27%) Grant income $1.6M $0.9M 92% Total revenue $ 8.1M $ 9.8M (17%) • Total revenue, including product sales and grant income was $8.1M in Q3 2022 compared to $9.8M

  8. Slide 8: Quarterly Product Sales

    Quarterly Product Sales Product Sales $12.0 Core Non-COVID-19 Product Sales COVID-19 Sales $2.5 $1.7 $10.0 $2.7 $1.8 $1.7 $2.4 $9.7 $1.1 $9.0 $7.6 $0.3 $8.0 $0.0 $8.3 $1.6 $8.0 $7.8 $7.5 $6.5 $0.0 $ IN MILLONS $7.3 $7.1 $6.6 $6.5 $6.0 $5.9 $5.7 $5.5 $5.2 $5.1 $4.6 $4.0 $4.4 $4.3 $3.4 $3.0 $2.6 $2.6

  9. Slide 9: Trailing Twelve Month Product Sales

    Trailing Twelve Month Product Sales $45.0 85% $7.1 $40.0 82% 80% 77% $35.0 $6.7 $2.0 $34.8 75% $30.0 72% 74% $2.7 $ IN MILLIONS 69% $29.4 70% AXIS TITLE $25.0 $27.8 68% $20.0 $21.6 64% 65% $19.1 $15.0 60% $10.0 $11.7 55% $5.0 $7.1 $0.0 50% Q3 2016 Q3 2017 Q3 2018 Q3 2019 Q3 2020 Q3 2021 Q3 2022 * Co

  10. Slide 10: Working Capital and Cap Table

    Working Capital and Cap Table Working Capital as of 9/30/2022 6/30/2022 3/31/2022 12/31/2021 9/30/2021 6/30/2021 3/31/2021 Current Assets: Cash and short-term investments* $22,552 $30,164 $43,023 $52,138 $61,043 $65,609 $68,468 Grants and accounts receivable, net 4,961 5,171 4,577 4,523 5,241 5,755

  11. Slide 11: Extending the Cash Runway

    Extending the Cash Runway • We have $24.2M in cash at September 30, 2022. We intend to further bolster our working capital by borrowing a portion of the $15M available debt facility before the end of 2022 • Cash conservation is a corporate priority, and we are continuing to focus on controlling expe

  12. Slide 12: Commercialization Update

    Commercialization Update Christian Steiner, MD Executive Vice President of Sales and Marketing Managing Director – CytoSorbents Europe GmbH

  13. Slide 13: State of the CytoSorb community; Growth opportunities and initiatives

    State of the CytoSorb community • High number of activities and customer interaction fuel the excitement • Growing support by key opinion leaders • Increasing involvement in CytoSorb projects / therapy optimization Growth opportunities and initiatives • Collaboration with Fresenius Medical Care (FMC

  14. Slide 14: CytoSorb movement is growing

    CytoSorb movement is growing CytoSorb World Users Meeting, July 1-3, Berlin, Germany • 300 KOLs from 39 countries; 26 speakers • Preview of new data sets in four different applications Italian Users Meeting (Aferetica), Sept 30/Oct 1, Milano, Italy • Focus on CytoSorb and Extracorporeal Organ Perfus

  15. Slide 15: Excitement at several conferences

    Excitement at several conferences Critical Care • COVID19 on ECMO+CytoSorb (CTC Registry) at ELSO in Boston, USA, and at ESICM in Paris, France Cardio Vascular • Infective Endocarditis at EACTS in Milano, Italy • Heart Transplantation at EACTS in Milano, Italy Liver / Kidney • Myoglobinemia at HAI i

  16. Slide 16: Excitement at several (many) conferences

    Excitement at several (many) conferences Conferences  Intensivmed Regensburg | 15. – 16.07.2022 | Germany  Herzanästhesie Graz | 24. – 25.06.2022 | Germany  Bielefelder Infektiologie- und Intensivtag | 27.08.2022 | Germany  BTS | 05.-07.09.2022 | Belfast  SATS Helsinki | 07. - 09.09.2022 | Finl

  17. Slide 17: Growth opportunities and initiatives

    Growth opportunities and initiatives Global marketing agreement with FMC • Expanding the dimensions of blood purification • CytoSorb as featured solution for FMC customers • Amplification of message / Awareness / Reach / Access Stand-alone blood pump strategy • Early stage of rollout, testing differ

  18. Slide 18: Clinical and Medical Update

    Clinical and Medical Update Efthymios N. Deliargyris, MD, FACC, FESC, FSCAI Chief Medical Officer

  19. Slide 19: Visibility & Prioritization

    Visibility & Prioritization • STAR-T is our “lead horse” to U.S. market and we are prioritizing resources to ensure speedy execution • STAR-T enrollment uptick with milestone #1 (n=40; DSMB) this month • FDA approval received to expand STAR-T to Canada, a ticagrelor “hotbed” • With better visibility

  20. Slide 20: STAR-T now with Visibility

    STAR-T now with Visibility • Increased number of study sites contributing with an uptick in enrollment • Milestone #1 (n=40) this month (PR to follow) triggering 1st DSMB review • FDA approval for Canada expansion. Potentially an important tailwind, since: • Canada is a Ticagrelor “hotbed” - ACS pro

  21. Slide 21: STAR-T: Rationale for focus and acceleration

    STAR-T: Rationale for focus and acceleration • STAR-T now executing well - we will devote our full attention and resources to fuel this momentum and speed up study completion • Canadian expansion with new Canadian ARO partner is projected to further accelerate enrollment, but to also has positive do

  22. Slide 22: STAR-D Update

    STAR-D Update • With our focus now on speeding up STAR-T completion, we will shift from a parallel to a sequential execution of the two studies • Accordingly, STAR-D activities will pause this month • There are no clinical/safety issues - This is solely a business decision • We remain fully committe

  23. Slide 23: Cardiac Surgery: Positive New Data (EACTS)

    Cardiac Surgery: Positive New Data (EACTS) Staph Aureus Antithrombotic Heart Endocarditis Removal Transplant • Better postoperative • 67% fewer transfusions • 58% lower rates of hemodynamic stabilization • 60% less chest tube postoperative vasoplegia • 63% reduction in sepsis- drainage • 62% shorter

  24. Slide 24: Critical Care: Final CTC Registry Results (ESICM)

    Critical Care: Final CTC Registry Results (ESICM) 100 patients 5 US Centers “Enhanced lung rest” ECMO + CytoSorb 74% 90-day survival - Largest and only multicenter ECMO+CytoSorb dataset - Higher survival than ECMO alone (ELSO Registry 52%) CONFIDENTIAL 24

  25. Slide 25: Clinical/Medical Summary

    Clinical/Medical Summary CLINICAL: • STAR-T accelerating plus new tailwind coming with addition of Canada • STAR-T with increased visibility - Milestone #1 this month; Milestone #2,3 next spring and summer respectively • Speedy execution of STAR-T top priority to capitalize on favorable dynamics • S

  26. Slide 26: Business Development

    Business Development Chris Cramer, MBA Vice President, Business Development

  27. Slide 27: Emerging New Opportunities to Expand the Pool of Transplantable Organs

    Emerging New Opportunities to Expand the Pool of Transplantable Organs with Ex-Vivo Perfusion and CytoSorbents Technology High Demand for More Transplants ~165,000 US and EU patients on transplant waiting list Annual Supply of Donors not Keeping Pace with Demand DBD: Donor after Brain Death DBD Dono

  28. Slide 28: Growing Base of Promising EVP Studies for CytoSorbents' Technology

    There is Growing Base of Promising EVP Studies for CytoSorbents’ Technology in Multiple Solid Organ Types Lung Kidney Liver Heart CytoSorbents Confidential 28

  29. Slide 29: ECOS-300CY is E.U. Cleared for Ex-Vivo Organ Perfusion

    ECOS-300CY is E.U. Cleared for Ex-Vivo Organ Perfusion and Ready to Support Multiple Partnering Opportunities • The ECOS-300CY sorbent cartridge has similar cytokine and inflammatory mediator removal capability to CytoSorb, but unlike CytoSorb, was specifically E.U. approved in October 2020 to remov

  30. Slide 30: Additional Partnering Opportunities Across the Organ Transplant Ecosystem

    Additional Partnering Opportunities Exist Across the Multi-Billion Dollar Organ Transplant Ecosystem Immunosuppressants Immunomodulators Organ Procurement Orgs. Ex-Vivo Perfusion Systems Intensive Care / Organ Support Surgical Equipment CytoSorbents Confidential 30

  31. Slide 31: Global Marketing Efforts with CytoSorb Featured on FMC Website

    Initiated Global Marketing Efforts with CytoSorb as a Featured Therapy on the FMC Corporate Website • FMC has begun marketing CytoSorb as a featured technology for cytokine, bilirubin, and myoglobin removal on its critical care platforms worldwide; CytoSorb can be found on FMC’s corporate website •

  32. Slide 32: Facility and Manufacturing Update

    Facility and Manufacturing Update Vincent Capponi, MS President and Chief Operating Officer

  33. Slide 33: Quarterly Progress: R&D, New Facility

    Quarterly Progress R&D New Facility 33

  34. Slide 34: R&D

    R&D • Grant programs continue to receive funding for the development of a wide range of products from removal of potassium, to anti-A and anti-B antibodies for blood transfusions. • The HemoDefend product family has received significant support from the U.S. Department of Defense with more than $17M

  35. Slide 35: Facility/Manufacturing Update

    Facility/Manufacturing Update Facility Update • ISO13485 certification for the new facility received in September • Transfer of polymer manufacturing to the new facility on track for December 2022 • Loss of product due to an equipment failure occurred in September translating into a spike in cost of

  36. Slide 36: Facility/Manufacturing Update: Inflation

    Facility/Manufacturing Update Inflation • Rising oil prices affecting raw material costs and transportations costs have pressured CytoSorb product cost • We have employed several mitigation strategies to reduce the impact of these raw material and transportation costs: • Large quantity purchases wit

  37. Slide 37: Concluding Remarks

    Concluding Remarks Phillip Chan, MD, PhD Chief Executive Officer

  38. Slide 38: Summary

    Summary • STAR-T is enrolling well and we expect to achieve the 1st milestone of STAR-T this month and are focusing our resources on driving this trial to completion, including adding Canadian centers. We have many reasons to prioritize this trial • We will temporarily pause STAR-D to focus on STAR-

  39. Slide 39: Q&A Session

    Q&A Session CytoSorbents Corporation NASDAQ: CTSO Company Contact Dr. Phillip Chan pchan@cytosorbents.com 39

CytoSorbents — Q3 2022 Earnings Presentation on 6ix